on Galimedix, Inc.
Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment
Galimedix Therapeutics is set to unveil new preclinical data at the AD/PD™ 2025 Conference, showcasing the potential of their amyloid-beta aggregation modulator, GAL-201, for oral Alzheimer's treatment. Results demonstrate its efficacy in mitigating Aβ-induced toxicity, positively impacting synaptic plasticity and neuroinflammation.
The company focuses on innovative oral therapies targeting misfolded amyloid-beta, aiming to prevent the toxic aggregates linked to Alzheimer's progression. GAL-201, alongside GAL-101, offers promise as a first-in-class treatment potentially altering disease trajectories.
The conference in Vienna will gather global experts to discuss advancements in neurodegenerative conditions, highlighting leading research and developments in Alzheimer's and related disorders.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galimedix, Inc. news